Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H18N2.ClH |
| Molecular Weight | 274.788 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CC(C2=CC=CC=C2)C3=C(C1)C(N)=CC=C3
InChI
InChIKey=QVRVDOKQQXBOLD-UHFFFAOYSA-N
InChI=1S/C16H18N2.ClH/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18;/h2-9,14H,10-11,17H2,1H3;1H
Nomifensine was developed by Hoechst AG as a potent inhibitor of noradrenaline, dopamine, and 5-HT uptake displayed antidepressant activity. It was first marketed in the UK in 1977 for the treatment of depression. Between 1977 and 1982 there were reports of hemolytic anemia in association with the drug, and this suspected adverse reaction was included in the 1981 edition of the data Sheet Compendium. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
84 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7082545 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NOMIFENSINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
53 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NOMIFENSINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
196.8 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7082545 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NOMIFENSINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7082545 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NOMIFENSINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.2 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NOMIFENSINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
25% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NOMIFENSINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
unhealthy, 18-44 years n = 18 Health Status: unhealthy Condition: attention deficit disorder Age Group: 18-44 years Sex: M+F Population Size: 18 Sources: |
Disc. AE: Skin rash, Fever... AEs leading to discontinuation/dose reduction: Skin rash (severe, 1 patient) Sources: Fever (severe, 1 patient) Back pain (severe, 1 patient) |
100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
healthy, 22-41 years Health Status: healthy Age Group: 22-41 years Sex: M+F Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Back pain | severe, 1 patient Disc. AE |
150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
unhealthy, 18-44 years n = 18 Health Status: unhealthy Condition: attention deficit disorder Age Group: 18-44 years Sex: M+F Population Size: 18 Sources: |
| Fever | severe, 1 patient Disc. AE |
150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
unhealthy, 18-44 years n = 18 Health Status: unhealthy Condition: attention deficit disorder Age Group: 18-44 years Sex: M+F Population Size: 18 Sources: |
| Skin rash | severe, 1 patient Disc. AE |
150 mg 2 times / day multiple, oral Studied dose Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: |
unhealthy, 18-44 years n = 18 Health Status: unhealthy Condition: attention deficit disorder Age Group: 18-44 years Sex: M+F Population Size: 18 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A comparison of the patterns of striatal Fos-like immunoreactivity induced by various dopamine agonists in rats. | 2000 Aug 4 |
|
| Characterization of the analgesic properties of nomifensine in rats. | 2001 Apr |
|
| Differential effect of quinpirole and 7-OH-DPAT on the spontaneous [(3)H]-dopamine efflux from rat striatal synaptosomes. | 2001 Apr |
|
| Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. | 2001 Aug 15 |
|
| Halothane decreases impulse-dependent but not cytoplasmic release of dopamine from rat striatal slices. | 2001 Dec |
|
| Determination of release and uptake parameters from electrically evoked dopamine dynamics measured by real-time voltammetry. | 2001 Dec 15 |
|
| Accumbens dopamine mechanisms in sucrose intake. | 2001 Jun 15 |
|
| Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes. | 2001 Mar |
|
| Nomifensine-induced c-fos mRNA expression in discrete brain areas of the developing rat. | 2001 May 4 |
|
| Nomifensine reveals age-related changes in K(+)-evoked striatal DA overflow in F344 rats. | 2001 May-Jun |
|
| Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. | 2001 Sep |
|
| Semicarbazide-sensitive amine oxidase (SSAO) in the brain. | 2002 Apr |
|
| Mechanism of action of methylmercury on in vivo striatal dopamine release. Possible involvement of dopamine transporter. | 2002 Apr |
|
| In vivo evidence for a lack of central effect of ebastine, an antihistaminic agent, in rats: a microdialysis study. | 2002 Dec |
|
| Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells. | 2002 Feb |
|
| NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. | 2002 Jan |
|
| Acute locomotor effects of fluoxetine, sertraline, and nomifensine in young versus aged Fischer 344 rats. | 2002 Jan-Feb |
|
| Ethanol-induced, nonexocytotic [3H]dopamine release from rat nucleus accumbens slices. | 2002 Jun |
|
| NMDA and AMPA/kainate glutamatergic agonists increase the extracellular concentrations of GABA in the prefrontal cortex of the freely moving rat: modulation by endogenous dopamine. | 2002 Mar 15 |
|
| Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. | 2002 May |
|
| Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. | 2002 May 17 |
|
| Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist. | 2002 Nov |
|
| GBR-12909 effect on dopamine outflow depends on phosphorylation in the caudate nucleus of the rat. | 2002 Nov |
|
| Kinetic analysis of striatal clearance of exogenous dopamine recorded by chronoamperometry in freely-moving rats. | 2002 Nov 15 |
|
| In vivo temporal sequence of rat striatal glutamate, aspartate and dopamine efflux during apomorphine, nomifensine, NMDA and PDC in situ administration. | 2002 Oct |
|
| Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis. | 2002 Oct |
|
| Identification of dopamine transporter in bovine pineal gland using [3H]GBR 12935. | 2003 Aug |
|
| Differential effects of amphetamine transport vs. dopamine reverse transport on particulate PKC activity in striatal synaptoneurosomes. | 2003 Aug |
|
| In vitro pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a nicotinic acetylcholine receptor ligand. | 2003 Aug 15 |
|
| Functionally distinct dopamine and octopamine transporters in the CNS of the cabbage looper moth. | 2003 Feb |
|
| Discriminative stimulus effects of (-)-ephedrine in rats: analysis with catecholamine transporter and receptor ligands. | 2003 Jun 5 |
|
| Aged Fischer 344 rats exhibit altered orolingual motor function: relationships with nigrostriatal neurochemical measures. | 2003 Mar-Apr |
|
| Differences in norepinephrine clearance in cerebellar slices from low-alcohol-sensitive and high-alcohol-sensitive rats. | 2003 May |
|
| Mechanisms underlying domoic acid-induced dopamine release from striatum: an in vivo microdialysis study. | 2003 Oct |
|
| Nomifensine amplifies subsecond dopamine signals in the ventral striatum of freely-moving rats. | 2004 Aug |
|
| Dopamine release evoked by beta scorpion toxin, tityus gamma, in prefrontal cortical slices is mediated by intracellular calcium stores. | 2004 Dec |
|
| Sibutramine induces potential-dependent exocytotic release but not carrier-mediated release of dopamine and 5-hydroxytryptamine. | 2004 Jan 26 |
|
| Methylphenidate restores ventral tegmental area dopamine neuron activity in prenatal ethanol-exposed rats by augmenting dopamine neurotransmission. | 2004 May |
|
| Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors. | 2004 Sep |
|
| D2 autoreceptor inhibition reveals oxygen-glucose deprivation-induced release of dopamine in guinea-pig cochlea. | 2005 |
|
| Dopamine transporter function differences between male and female CD-1 mice. | 2005 Feb 28 |
|
| Dopamine transporters are involved in the onset of hypoxia-induced dopamine efflux in striatum as revealed by in vivo microdialysis. | 2005 Jun |
|
| Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. | 2005 Mar |
|
| Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra. | 2005 Mar |
|
| Nicotine and epibatidine alter differently nomifensine-elevated dopamine output in the rat dorsal and ventral striatum. | 2005 Mar 28 |
Patents
Sample Use Guides
The effect of nomifensine on the uptake of 5-hydroxytryptamine (5-HT) and dopamine (DA) into human platelet-rich plasma has been studied. A significant inhibition of DA uptake was observed at nomifensine 10(-6) M. 5-HT uptake was significantly inhibited only at nomifensine 10(-4) M or more. It was concluded, that the human platelet may be used as a model for studying DA uptake as well as that of 5-HT.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8HJ6V99LZB
Created by
admin on Sat Dec 16 09:55:48 GMT 2023 , Edited by admin on Sat Dec 16 09:55:48 GMT 2023
|
PRIMARY | |||
|
98159-56-9
Created by
admin on Sat Dec 16 09:55:48 GMT 2023 , Edited by admin on Sat Dec 16 09:55:48 GMT 2023
|
PRIMARY | |||
|
147520
Created by
admin on Sat Dec 16 09:55:48 GMT 2023 , Edited by admin on Sat Dec 16 09:55:48 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
